 This study will test the early and late toxicities of selumetinib when it is given in this intermittent schedule in 5 out of 7 days and will also test the effectiveness of the drug in reducing the size of plexiform neurofibromas and optic pathway gliomas in children with NF1. It will also test the effectiveness of the drug in improving the participants function in day to day life. 